Stock AGTX AGENTIX CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Agentix Corp.

Equities

AGTX

US00848A1034

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 11:24:38 2024-03-21 am EDT 		5-day change 1st Jan Change
0.0322 USD +0.31% Intraday chart for Agentix Corp. -.--% +3.87%
Feb. 14 Agentix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
2023 Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI

Valuation

Fiscal Period: März 2021 2022 2023
Capitalization 1 24.48 9.83 3.912
Enterprise Value (EV) 1 24.48 9.83 3.949
P/E ratio -14.1 x -2.35 x -2.86 x
Yield - - -
Capitalization / Revenue 19,743,525,806 x - -
EV / Revenue 19,742,100,000 x - -
EV / EBITDA - - -
EV / FCF 299,837,149 x - 9,520,027 x
FCF Yield 0% - 0%
Price to Book -44.1 x -9.13 x -1.78 x
Nbr of stocks (in thousands) 34,875 38,917 39,117
Reference price 2 0.7020 0.2526 0.1000
Announcement Date 7/18/22 7/18/22 7/14/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2020 2021 2022 2023
Net sales - 0.00124 - -
EBITDA - - - -
EBIT 1 -0.8265 -1.723 -3.928 -1.372
Operating Margin - -138,937.9% - -
Earnings before Tax (EBT) 1 -0.8734 -1.723 -3.928 -1.374
Net income 1 -0.8734 -1.723 -3.928 -1.374
Net margin - -138,937.18% - -
EPS 2 -0.0377 -0.0499 -0.1074 -0.0350
Free Cash Flow - 0.0816 - 0.4148
FCF margin - 6,584.27% - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 12/9/20 7/18/22 7/18/22 7/14/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: März 2020 2021 2022 2023
Net Debt 1 - - - 0.04
Net Cash position 1 0.24 0 0 -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - 0.08 - 0.41
ROE (net income / shareholders' equity) - 807% - 82.6%
ROA (Net income/ Total Assets) - -487% - -618%
Assets 1 - 0.3537 - 0.2222
Book Value Per Share 2 0.0100 -0.0200 -0.0300 -0.0600
Cash Flow per Share 2 0.0100 0 0 0
Capex - - - -
Capex / Sales - - - -
Announcement Date 12/9/20 7/18/22 7/18/22 7/14/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
AGENTIX CORP. Stock Agentix Corp.
+3.87% 1.29M
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. AGTX Stock
  4. Financials Agentix Corp.